F044 AAD Hair Loss and Alopecia Initiative in Research (HAIR) Grant Program - Embracing Diversity in Hair Disorders Research
DESCRIPTION
Open admission to eligible categories, no tuition or ticket
Hair loss among diverse populations and skin of color have been underfunded. Since 2021, HAIR research grants have been offered to dermatologists, researchers, and trainees in the United States for basic, translational, and/or clinical research projects that address gaps in hair disorders research, with emphasis on hair disorders in diverse populations. This session will describe the HAIR grant research program and projects funded to date.
LEARNING OBJECTIVES
Discuss the goals of the HAIR grant program in terms of underfunded research initiatives in diverse populations and/or skin of color
Identify areas of research considered a priority via this grant including central centrifugal cicatricial alopecia, traction alopecia, and areas of racial differences or disparities in care involving androgenetic alopecia in women, frontal fibrosing alopecia, lichen planopilaris, the role of nutrition in hair loss, and environmental/genetic factors in hair loss.
Provide progress and research updates from HAIR research grants awarded in 2022
SCHEDULE
6:00 PM
Introduction
Wilma Fowler Bergfeld, MD, FAAD
6:05 PM
Mast cells in central centrifugal cicatricial alopecia
Lynne J. Goldberg, MD, FAAD
6:30 PM
The impact of hair washing on scalp cytokine expression in patients with CCCA
Crystal Aguh, MD, FAAD
7:00 PM
Spatial transcriptomics identifies potential therapeutic targets for CCCA
John T. Seykora, PhD, MD
7:30 PM
The microbiome of the scalp skin
Ronda S. Farah, MD, FAAD
7:55 PM
Summary
SPEAKERS
Crystal Aguh, MD, FAAD
Wilma Fowler Bergfeld, MD, FAAD
Ronda S. Farah, MD, FAAD
Lynne J. Goldberg, MD, FAAD
John T. Seykora, PhD, MD
HANDOUTS
SPEAKER DISCLOSURES
Crystal Aguh, MD, FAAD
CP Skin Health – Advisory Board(Honoraria); Eli Lilly and Company – Consultant(Fees); janssen – Other(Residency/Fellowship Program Funding); Myovant Sciences – Advisory Board(Fees); Olaplex – Advisory Board(Fees); Pfizer Inc. – Consultant(Fees); Procter & Gamble Company – Consultant (1099 relationship)(Fees); UpToDate, Inc – Other(Fees);
Wilma Fowler Bergfeld, MD, FAAD
No financial relationships exist with ineligible companies.
Ronda S. Farah, MD, FAAD
American Academy of Dermatology – Other(Grants/Research Funding); Arcutis, Inc. – Investigator(Grants/Research Funding); ASLAN Pharmaceuticals – Investigator(Grants/Research Funding); Concert Pharmaceuticals – Investigator(Grants/Research Funding); Early Sullivan Wright Gizer & McRae LLP – Consultant (1099 relationship)(Fees); Eli Lilly – Investigator(Grants/Research Funding); Lumenis Be Ltd. – Consultant (1099 relationship)(Fees); Novartis – Advisory Board(Fees); Pfizer – Investigator(Grants/Research Funding); Pfizer Inc. – Stockholder(No Compensation Received), Stockholder Public Company(No Compensation Received); Technoderma Medicines – Investigator(Grants/Research Funding);
Lynne J. Goldberg, MD, FAAD
UpToDate, Inc – Other(Fees);
John T. Seykora, PhD, MD
Almirall – Investigator(Grants/Research Funding); Calico Laboratories – Investigator(Grants/Research Funding); Merck & Co., Inc – Consultant(Fees), Investigator(Grants/Research Funding); PIQUR Therapeutics – Investigator(Grants/Research Funding); Rohto Pharmaceutical – Investigator(Grants/Research Funding);